Funding round completed
SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, thas closed a €15.7 million Series B financing round. Lead investors are Munich-based MIG AG and BioMedInvest AG from Basel, Switzerland. Santo Holding GmbH and existing investors ZETACUBE s.r.l., KfW Mittelstandsbank, Bayern Kapital GmbH and the Max-Planck-Gesellschaft also participated in the round.
The company was founded in 2002 as a spin-off from the Max Planck Institute for Biochemistry in Martinsried, near Munich, by 1988 Nobel Chemistry laureate Robert Huber, Uwe Jacob and Peter Sondermann. The company uses its expertise in purification, crystallisation, and X-ray diffraction analysis of Fc-receptors to develop next generation therapies for autoimmune diseases. Its lead programme, SM101, is a soluble human Fc-receptor that binds to immune complexes and down-regulates inflammation, cellular immune response, and B-cell activation.
The company says that this novel approach could lead to potentially curing, rather than merely treating, autoimmune disorders such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and rheumatoid arthritis.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
